Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

2nd Annual International OSD Review

By: Prof. James Wolffsohn Chair, Mr. Arthur Cummings, Dr. Marguerite McDonald MD, Dr. Charles Flowers, MD

Webinar Credits: 1

A discussion of the progress of the DEWS II TFOS report particularly with a view on what has changed in practice and what more can be derived from the report.

Expiration Date: Sunday, February 28, 2021
Release Date: February 24, 2020

Learning Objectives

  • Describe the myriad symptoms and signs of dry eye disease (DED)
  • Translate and apply the dry eye diagnosis and treatment strategies outlined in the TFOS Dews II Report
  • Compare the approach to dry eye management in clinical practice vs from how it was outlined in the TFOS DEWS II Report
  • Assess the reasons why it’s important to optimize the tear film before any ocular surgical procedure
  • Devise an individualized DED treatment plan

 

References:

Baudouin C, Aragona P, Van Setten G, et al; ODISSEY European Consensus Group members. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014;98(9):1168-1176.

Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300-306.

Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.

Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification Report. Ocul Surf. 2017;15:276-283.

Dohlman TH, Ciralsky JB, Lai EC.Tear film assessments for the diagnosis of dry eye. Curr Opin Allergy Clin Immunol.2016;16(5):487-491.

Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511-538.

Jones L, Downie DE, Donald Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628.

Lemp M, Crews L, Bro A, et al. Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort: A Retrospective Study Cornea. 2012; 31(5):472-478.

Majmudar PA. CEDARS Dry Eye Algorithm. Ophthalmology Management. https://www.ophthalmologymanagement.com/newsletters/ocular-surface-news-for-mds/february-27,-2019. Updated Feb. 27, 2019. Accessed February 25, 2020.

Millán A, Eloy V, Gude F et al; Incidence and risk factors of dry eye in a Spanish adult population: 11-year follow-up from the Salnés Eye Study. Cornea. 2018;37(12):1527-1534.

Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929.

Ong ES, Felix ER, Levitt RC, Feuer WJ, et al. Epidemiology of discordance between symptoms and signs of dry eye. Br J Ophthalmol. 2018;102(5):674-679.

Pult H, Wolffsohn JS. The development and evaluation of the new Ocular Surface Disease Index-6. Ocul Surf. 2019;17(4):817-821.

Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence, measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.

Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-365.

Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthal Vis Sci. 2010;51(12):6125-6130.

Sutu C, Fukuoka H, Afshar N. Mechanisms and management of dry eye in cataract surgery patients. Curr Opin Ophthalmol. 2016;27(1):24–30.

Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15; 539-574.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Arthur Cummings MD, and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Scope Ophthalmics, Tearclear, Wavelight, and Vivior. Grant Research Support: Alcon, Allotex, and RXSight. Speaker’s Bureau: Alcon, TearLab, Wavelight, and Vivior. Share/Stockholder: Alcon, and Novartis.

Charles Flowers, MD, and or spouse, has had no affiliations with commercial interests.

Professor James Wolffsohn and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, plc., Bausch + Lomb, Coopervision, Nevakar, Novartis, and RB. Grant Research Support: Allergan, Johnson & Johnson, Rayner, Innovate, U.K. Share/Stockholder: Eyoto.

Marguerite McDonald and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, plc., Bausch + Lomb, Johnson & Johnson Vision, Ocusoft, and Scope Ophthalmics.

 

Editorial Support Disclosures:

Erin K. Fletcher, MIT, director of compliance and education, Cassandra Richards, director of education development, Evolve, has no financial relationships with commercial interests.  Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Scope Ophthalmic.

Pretest

Video Resources

Next

Test

Instructions

Step 1 of 2

50%
  • AgreeNeutralDisagree
    • Describe the myriad symptoms and signs of dry eye disease (DED)
    • Translate and apply the dry eye diagnosis and treatment strategies outlined in the TFOS Dews II Report
    • Compare the approach to dry eye management in clinical practice vs from how it was outlined in the TFOS DEWS II Report
    • Assess the reasons why it’s important to optimize the tear film before any ocular surgical procedure
    • Devise an individualized DED treatment plan
Back